Transaction Description
Gemstone Capital acted as financial advisor in Prostatype Genomics’ warrant exercise. The subscription price for the TO 4 was set at 5.96 SEK per share, corresponding to 70 percent of the volume-weighted average price of the Company’s share during the period 11 November to 22 November 2024. If all warrants of series TO 4 were exercised, the Company would receive approximately 9.9 million SEK before issue related costs. The dilution if all warrants were exercised amounted to approximately 24.4 percent to the capital and number of votes. A total of 1,556,419,000 warrants of series TO 4, corresponding to an exercise rate of approximately 93.6 percent, were exercised for subscription of 1,556,419 new shares in the Company. The Company thus received approximately SEK 9.3 million through the exercise of TO 4 before deduction of issue costs.
Contact Person
Company Description
Prostate cancer is one of the most common forms of cancer and approximately 1.3 million men are diagnosed annually. Prostatype Genomics has developed an algorithm-based kit specifically designed to eliminate the misclassification of prostate cancer, which can lead to inappropriate treatment and dosages. Such misclassification often results in unnecessary side effects and requires multiple treatment courses. This innovative kit seamlessly integrates with current diagnostic procedures and tests, ensuring no disruption to the existing healthcare process.
